Currently approved clinical therapeutics that target indirectly the VHL/HIF-α axis, which include angiogenesis and mTOR kinase inhibitors, achieve only modest improvements in RCC patient survival [13]. This evidence concerns the gene MTOR and renal cell carcinoma.